Leber's congenital amaurosis (LCA) is a rare inherited eye disease that presents itself at birth or in the first few months after birth. The vision-destroying genetic mutation can now be treated with Luxturna, a gene therapy injection that replaces a defective gene, which prevents the retina from converting light into electronic signals sent to the brain, with a corrective gene. LCA induced blindness only impacts a small group of Americans, but the FDA approved intervention is a significant advancement in the field of vision loss.
 
"One of the best things I've ever seen since surgery are the stars. I never knew that they were little dots that twinkled," said Mistie Lovelace of Kentucky, one of several patients who urged the FDA to approve the therapy at a public hearing in October.

If you are experiencing blindness, SDCB can help you improve your quality of life.

"FDA approves gene therapy for rare form of blindness"